NBTXR3 doubles pathological complete response in STS patients

Bulletin Cancer, 2019, Khalladi N. & Thariat J.

Authors

Nazim Khalladi1, Juliette Thariat1,2

1 – Centre François-Baclesse/ARCHADE, Department of Radiation, Oncology, 3, avenue Général-Harris, 14000 Caen, France
2 – Normandie université, UNICAEN, ENSICAEN, CNRS/IN2P3, LPC Caen,14000 Caen, France

Summary

Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial